Department of Health and Human Services January 5, 2009 – Federal Register Recent Federal Regulation Documents

National Center for Research Resources; Notice of Closed Meeting
Document Number: E8-31388
Type: Notice
Date: 2009-01-05
Agency: Department of Health and Human Services, National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting
Document Number: E8-31378
Type: Notice
Date: 2009-01-05
Agency: Department of Health and Human Services, National Institutes of Health
National Institute of Dental & Craniofacial Research; Notice of Closed Meetings
Document Number: E8-31376
Type: Notice
Date: 2009-01-05
Agency: Department of Health and Human Services, National Institutes of Health
Agency Information Collection Request. 60-Day Public Comment Request
Document Number: E8-31375
Type: Notice
Date: 2009-01-05
Agency: Department of Health and Human Services
Part C Early Intervention Services Grant
Document Number: E8-31373
Type: Notice
Date: 2009-01-05
Agency: Department of Health and Human Services, Health Resources and Services Administration
HRSA will be providing temporary critical HIV medical care and treatment services through the Medical Center of Louisiana at New Orleans to avoid a disruption of HIV clinical care to clients in Orleans Parish in Louisiana.
Board of Scientific Counselors, National Center for Health Statistics, (BSC, NCHS)
Document Number: E8-31340
Type: Notice
Date: 2009-01-05
Agency: Centers for Disease Control and Prevention, Department of Health and Human Services
Guidance for Industry on Labeling Over-the-Counter Human Drug Products-Questions and Answers; Availability
Document Number: E8-31321
Type: Notice
Date: 2009-01-05
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA) is announcing the availability of a guidance for industry entitled ``Labeling OTC Human Drug ProductsQuestions and Answers.'' This guidance is intended to assist manufacturers, packers, and distributors of over-the-counter (OTC) drug products in complying with the agency's regulation on standardized content and format requirements for the labeling of OTC drug products. This guidance primarily discusses labeling questions that have been frequently asked by manufacturers, packers, and distributors relating to these requirements. The labeling examples in this guidance show various format and content features and suggest how OTC drug monograph labeling information finalized before the new requirements can be converted to the new format. This guidance finalizes the draft guidance of the same name published January 13, 2005 (70 FR 2415).
Training Program for Regulatory Project Managers; Information Available to Industry
Document Number: E8-31320
Type: Notice
Date: 2009-01-05
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) is announcing the continuation of the Regulatory Project Management Site Tours and Regulatory Interaction Program (the Site Tours Program). The purpose of this document is to invite pharmaceutical companies interested in participating in this program to contact CDER.
Draft Guidance for Industry and Food and Drug Administration Staff; Assay Migration Studies for In Vitro Diagnostic Devices; Availability
Document Number: E8-31319
Type: Notice
Date: 2009-01-05
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA) is announcing the availability of the draft guidance entitled ``Assay Migration Studies for In Vitro Diagnostic Devices.'' This draft guidance presents a least burdensome regulatory approach to gaining FDA approval of Class III or certain licensed in vitro diagnostic devices in cases when a previously approved assay is migrating (i.e., transitioning) to a New System for which the assay has not been previously approved or licensed.
Agency Information Collection Activities: Submission for OMB Review; Comment Request
Document Number: E8-31301
Type: Notice
Date: 2009-01-05
Agency: Department of Health and Human Services, Substance Abuse and Mental Health Services Administration
Agency Information Collection Activities: Proposed Collection; Comment Request
Document Number: E8-31299
Type: Notice
Date: 2009-01-05
Agency: Department of Health and Human Services, Substance Abuse and Mental Health Services Administration
Listing of Color Additives Exempt From Certification; Food, Drug, and Cosmetic Labeling: Cochineal Extract and Carmine Declaration
Document Number: E8-31253
Type: Rule
Date: 2009-01-05
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA) is revising its requirements for cochineal extract and carmine by requiring their declaration by name on the label of all food and cosmetic products that contain these color additives. This final rule responds to reports of severe allergic reactions, including anaphylaxis, to cochineal extract- containing food and carmine-containing food and cosmetics and will allow consumers who are allergic to these color additives to identify and thus avoid products that contain these color additives. This action also responds to a citizen petition submitted by the Center for Science in the Public Interest (CSPI).
``Guidance for Industry: Substantiation for Dietary Supplement Claims Made Under Section 403(r)(6) of the Federal Food, Drug, and Cosmetic Act;'' Availability
Document Number: E8-31249
Type: Notice
Date: 2009-01-05
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA) is announcing the availability of a guidance entitled ``Guidance for Industry: Substantiation for Dietary Supplement Claims Made Under Section 403(r)(6) of the Federal Food, Drug, and Cosmetic Act.'' The guidance describes the amount, type, and quality of evidence that FDA recommends a manufacturer have to substantiate a claim under this section of the Federal Food, Drug, and Cosmetic Act (the act).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.